Vivek Subbiah
MD
Associate Professor, Early Drug Development
👥Biography 个人简介
Vivek Subbiah led key early-phase trials of selpercatinib (LOXO-292) for RET-altered cancers, establishing its efficacy in RET fusion-positive NSCLC and medullary thyroid cancer. He has been an advocate for tumor-agnostic drug development and conducts biomarker-driven basket trials. His research spans rare oncogenic alterations including NTRK, RET, and NRG1 fusions.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Vivek Subbiah 的研究动态
Follow Vivek Subbiah's research updates
留下邮箱，当我们发布与 Vivek Subbiah（Sarah Cannon Research Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment